Skip to main content
Top
Published in: BMC Urology 1/2019

Open Access 01-12-2019 | Metastasis | Research article

Association between De Ritis ratio (aspartate aminotransferase/alanine aminotransferase) and oncological outcomes in bladder cancer patients after radical cystectomy

Authors: Yun-Sok Ha, Sang Won Kim, So Young Chun, Jae-Wook Chung, Seock Hwan Choi, Jun Nyung Lee, Bum Soo Kim, Hyun Tae Kim, Eun Sang Yoo, Tae Gyun Kwon, Won Tae Kim, Wun-Jae Kim, Tae-Hwan Kim

Published in: BMC Urology | Issue 1/2019

Login to get access

Abstract

Background

New biological prognostic predictors have been studied; however, some factors have limited clinical application due to tissue-specific expression and high cost. There is the need for a promising predictive factor that is simple to detect and that is closely linked to oncological outcomes in patients with urothelial bladder cancer (BC) who have undergone radical cystectomy (RC). Therefore, we investigated the clinical prognostic value of the preoperative De Ritis ratio (aspartate aminotransferase/alanine aminotransferase) on oncological outcomes in patients with urothelial BC after RC.

Methods

We retrospectively evaluated clinicopathological data of 118 patients with non-metastatic urothelial BC after RC between 2008 and 2013 at a single center. The association between the De Ritis ratio and clinicopathological findings was assessed. The potential prognostic value of the De Ritis ratio was analyzed using the Kaplan-Meier method, and multivariate Cox analyses were performed to identify the independent predictors of metastasis-free survival, cancer-specific survival, and overall survival.

Results

According to the receiver operating curve of the De Ritis ratio for metastasis, we stratified the patients into 2 groups using a threshold of 1.3. A high De Ritis ratio was more likely to be associated with old age and the female sex. Kaplan-Meier estimates revealed that patients with a high De Ritis ratio had inferior metastasis-free survival, cancer-specific survival, and overall survival outcomes (P = 0.012, 0.024, and 0.022, respectively). Multivariate analysis revealed that a high De Ritis ratio was an independent prognostic factor for metastasis (hazard ratio [HR], 2.389; 95% confidence interval [CI], 1.161–4.914; P = 0.018), cancer-related death (HR, 2.755; 95% CI, 1.214–6.249; P = 0.015), and overall death (HR, 2.761; 95% CI, 1.257–6.067; P = 0.011).

Conclusions

An elevated De Ritis ratio was significantly associated with worse prognosis in patients who underwent RC for urothelial BC. This ratio might further improve the predictive accuracy for prognosis in BC.
Literature
1.
go back to reference Ha YS, Kim TH. Chemotherapy in advanced urothelial carcinoma. Korean J Urol Oncol. 2016;14(2):47–53.CrossRef Ha YS, Kim TH. Chemotherapy in advanced urothelial carcinoma. Korean J Urol Oncol. 2016;14(2):47–53.CrossRef
2.
go back to reference Oh CM, Won YJ, Jung KW, Kong HJ, Cho H, Lee JK, Lee DH, Lee KH, Community of Population-Based Regional Cancer R. Cancer Statistics in Korea: Incidence, Mortality, Survival, and Prevalence in 2013. Cancer Res Treat. 2016;48(2):436–50.PubMedPubMedCentralCrossRef Oh CM, Won YJ, Jung KW, Kong HJ, Cho H, Lee JK, Lee DH, Lee KH, Community of Population-Based Regional Cancer R. Cancer Statistics in Korea: Incidence, Mortality, Survival, and Prevalence in 2013. Cancer Res Treat. 2016;48(2):436–50.PubMedPubMedCentralCrossRef
3.
go back to reference Jung KW, Won YJ, Oh CM, Kong HJ, Cho H, Lee JK, Lee DH, Lee KH. Prediction of Cancer incidence and mortality in Korea, 2016. Cancer Res Treat. 2016;48(2):451–7.PubMedPubMedCentralCrossRef Jung KW, Won YJ, Oh CM, Kong HJ, Cho H, Lee JK, Lee DH, Lee KH. Prediction of Cancer incidence and mortality in Korea, 2016. Cancer Res Treat. 2016;48(2):451–7.PubMedPubMedCentralCrossRef
4.
go back to reference Stein JP, Skinner DG. Radical cystectomy for invasive bladder cancer: long-term results of a standard procedure. World J Urol. 2006;24(3):296–304.PubMedCrossRef Stein JP, Skinner DG. Radical cystectomy for invasive bladder cancer: long-term results of a standard procedure. World J Urol. 2006;24(3):296–304.PubMedCrossRef
5.
go back to reference Grossman HB, Natale RB, Tangen CM, Speights VO, Vogelzang NJ, Trump DL, deVere White RW, Sarosdy MF, Wood DP Jr, Raghavan D, et al. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N Engl J Med. 2003;349(9):859–66.PubMedCrossRef Grossman HB, Natale RB, Tangen CM, Speights VO, Vogelzang NJ, Trump DL, deVere White RW, Sarosdy MF, Wood DP Jr, Raghavan D, et al. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N Engl J Med. 2003;349(9):859–66.PubMedCrossRef
6.
go back to reference Advanced Bladder Cancer Meta-analysis C. Neoadjuvant chemotherapy in invasive bladder cancer: update of a systematic review and meta-analysis of individual patient data advanced bladder cancer (ABC) meta-analysis collaboration. Eur Urol. 2005;48(2):202–5 discussion 205–206.CrossRef Advanced Bladder Cancer Meta-analysis C. Neoadjuvant chemotherapy in invasive bladder cancer: update of a systematic review and meta-analysis of individual patient data advanced bladder cancer (ABC) meta-analysis collaboration. Eur Urol. 2005;48(2):202–5 discussion 205–206.CrossRef
7.
go back to reference Herr HW, Dotan Z, Donat SM, Bajorin DF. Defining optimal therapy for muscle invasive bladder cancer. J Urol. 2007;177(2):437–43.PubMedCrossRef Herr HW, Dotan Z, Donat SM, Bajorin DF. Defining optimal therapy for muscle invasive bladder cancer. J Urol. 2007;177(2):437–43.PubMedCrossRef
8.
go back to reference De Ritis F, Coltorti M, Giusti G. An enzymic test for the diagnosis of viral hepatitis; the transaminase serum activities. Clin Chim Acta. 1957;2(1):70–4.CrossRef De Ritis F, Coltorti M, Giusti G. An enzymic test for the diagnosis of viral hepatitis; the transaminase serum activities. Clin Chim Acta. 1957;2(1):70–4.CrossRef
9.
go back to reference Lindmark G, Gerdin B, Pahlman L, Bergstrom R, Glimelius B. Prognostic predictors in colorectal cancer. Dis Colon Rectum. 1994;37(12):1219–27.PubMedCrossRef Lindmark G, Gerdin B, Pahlman L, Bergstrom R, Glimelius B. Prognostic predictors in colorectal cancer. Dis Colon Rectum. 1994;37(12):1219–27.PubMedCrossRef
10.
go back to reference Kiba T, Ito T, Nakashima T, Okikawa Y, Kido M, Kimura A, Kameda K, Miyamae F, Tanaka S, Atsumi M, et al. Bortezomib and dexamethasone for multiple myeloma: higher AST and LDH levels associated with a worse prognosis on overall survival. BMC Cancer. 2014;14:462.PubMedPubMedCentralCrossRef Kiba T, Ito T, Nakashima T, Okikawa Y, Kido M, Kimura A, Kameda K, Miyamae F, Tanaka S, Atsumi M, et al. Bortezomib and dexamethasone for multiple myeloma: higher AST and LDH levels associated with a worse prognosis on overall survival. BMC Cancer. 2014;14:462.PubMedPubMedCentralCrossRef
11.
go back to reference Stocken DD, Hassan AB, Altman DG, Billingham LJ, Bramhall SR, Johnson PJ, Freemantle N. Modelling prognostic factors in advanced pancreatic cancer. Br J Cancer. 2008;99(6):883–93.PubMedPubMedCentralCrossRef Stocken DD, Hassan AB, Altman DG, Billingham LJ, Bramhall SR, Johnson PJ, Freemantle N. Modelling prognostic factors in advanced pancreatic cancer. Br J Cancer. 2008;99(6):883–93.PubMedPubMedCentralCrossRef
12.
go back to reference Bezan A, Mrsic E, Krieger D, Stojakovic T, Pummer K, Zigeuner R, Hutterer GC, Pichler M. The preoperative AST/ALT (De Ritis) ratio represents a poor prognostic factor in a cohort of patients with nonmetastatic renal cell carcinoma. J Urol. 2015;194(1):30–5.PubMedCrossRef Bezan A, Mrsic E, Krieger D, Stojakovic T, Pummer K, Zigeuner R, Hutterer GC, Pichler M. The preoperative AST/ALT (De Ritis) ratio represents a poor prognostic factor in a cohort of patients with nonmetastatic renal cell carcinoma. J Urol. 2015;194(1):30–5.PubMedCrossRef
13.
go back to reference Nishikawa M, Miyake H, Fujisawa M. De Ritis (aspartate transaminase/alanine transaminase) ratio as a significant predictor of recurrence-free survival in patients with upper urinary tract urothelial carcinoma following nephroureterectomy. Urol Oncol. 2016;34(9):417 e419–5.CrossRef Nishikawa M, Miyake H, Fujisawa M. De Ritis (aspartate transaminase/alanine transaminase) ratio as a significant predictor of recurrence-free survival in patients with upper urinary tract urothelial carcinoma following nephroureterectomy. Urol Oncol. 2016;34(9):417 e419–5.CrossRef
14.
go back to reference Yun SJ, Jo SW, Ha YS, Lee OJ, Kim WT, Kim YJ, Lee SC, Kim WJ. PFKFB4 as a prognostic marker in non-muscle-invasive bladder cancer. Urol Oncol. 2012;30(6):893–9.PubMedCrossRef Yun SJ, Jo SW, Ha YS, Lee OJ, Kim WT, Kim YJ, Lee SC, Kim WJ. PFKFB4 as a prognostic marker in non-muscle-invasive bladder cancer. Urol Oncol. 2012;30(6):893–9.PubMedCrossRef
15.
go back to reference Chang SG, Lee JH, Hong DH, Lee HL, Chai SE, Hoffman RM. Comparison of glucose-consumption and thymidine-incorporation endpoints in histocultured human superficial bladder tumors. Anticancer Res. 1994;14(1A):77–83.PubMed Chang SG, Lee JH, Hong DH, Lee HL, Chai SE, Hoffman RM. Comparison of glucose-consumption and thymidine-incorporation endpoints in histocultured human superficial bladder tumors. Anticancer Res. 1994;14(1A):77–83.PubMed
16.
go back to reference Stein JP, Quek ML, Skinner DG. Lymphadenectomy for invasive bladder cancer. II. Technical aspects and prognostic factors. BJU Int. 2006;97(2):232–7.PubMedCrossRef Stein JP, Quek ML, Skinner DG. Lymphadenectomy for invasive bladder cancer. II. Technical aspects and prognostic factors. BJU Int. 2006;97(2):232–7.PubMedCrossRef
17.
18.
go back to reference Bak DJ, Lee YJ, Woo MJ, Chung JW, Ha YS, Kim HT, Kim TH, Yoo ES, Kim BW, Kwon TG. Complications and oncologic outcomes following robot-assisted radical cystectomy: what is the real benefit? Investig Clin Urol. 2016;57(4):260–7.PubMedPubMedCentralCrossRef Bak DJ, Lee YJ, Woo MJ, Chung JW, Ha YS, Kim HT, Kim TH, Yoo ES, Kim BW, Kwon TG. Complications and oncologic outcomes following robot-assisted radical cystectomy: what is the real benefit? Investig Clin Urol. 2016;57(4):260–7.PubMedPubMedCentralCrossRef
19.
go back to reference Menon M, Hemal AK, Tewari A, Shrivastava A, Shoma AM, El-Tabey NA, Shaaban A, Abol-Enein H, Ghoneim MA. Nerve-sparing robot-assisted radical cystoprostatectomy and urinary diversion. BJU Int. 2003;92(3):232–6.PubMedCrossRef Menon M, Hemal AK, Tewari A, Shrivastava A, Shoma AM, El-Tabey NA, Shaaban A, Abol-Enein H, Ghoneim MA. Nerve-sparing robot-assisted radical cystoprostatectomy and urinary diversion. BJU Int. 2003;92(3):232–6.PubMedCrossRef
20.
go back to reference Osunkoya AO, Grignon DJ. Practical issues and pitfalls in staging tumors of the genitourinary tract. Semin Diagn Pathol. 2012;29(3):154–66.PubMedCrossRef Osunkoya AO, Grignon DJ. Practical issues and pitfalls in staging tumors of the genitourinary tract. Semin Diagn Pathol. 2012;29(3):154–66.PubMedCrossRef
21.
go back to reference Lopez-Beltran A, Bassi P, Pavone-Macaluso M, Montironi R. Handling and pathology reporting of specimens with carcinoma of the urinary bladder, ureter, and renal pelvis. Eur Urol. 2004;45(3):257–66.PubMedCrossRef Lopez-Beltran A, Bassi P, Pavone-Macaluso M, Montironi R. Handling and pathology reporting of specimens with carcinoma of the urinary bladder, ureter, and renal pelvis. Eur Urol. 2004;45(3):257–66.PubMedCrossRef
22.
go back to reference Vrooman OP, Witjes JA. Follow-up of patients after curative bladder cancer treatment: guidelines vs. practice. Curr Opin Urol. 2010;20(5):437–42.PubMedCrossRef Vrooman OP, Witjes JA. Follow-up of patients after curative bladder cancer treatment: guidelines vs. practice. Curr Opin Urol. 2010;20(5):437–42.PubMedCrossRef
23.
go back to reference Prout GR Jr, Wesley MN, Yancik R, Ries LA, Havlik RJ, Edwards BK. Age and comorbidity impact surgical therapy in older bladder carcinoma patients: a population-based study. Cancer. 2005;104(8):1638–47.PubMedCrossRef Prout GR Jr, Wesley MN, Yancik R, Ries LA, Havlik RJ, Edwards BK. Age and comorbidity impact surgical therapy in older bladder carcinoma patients: a population-based study. Cancer. 2005;104(8):1638–47.PubMedCrossRef
24.
go back to reference Witjes JA, Comperat E, Cowan NC, De Santis M, Gakis G, Lebret T, Ribal MJ, Van der Heijden AG, Sherif A, European Association of U. EAU guidelines on muscle-invasive and metastatic bladder cancer: summary of the 2013 guidelines. Eur Urol. 2014;65(4):778–92.PubMedCrossRef Witjes JA, Comperat E, Cowan NC, De Santis M, Gakis G, Lebret T, Ribal MJ, Van der Heijden AG, Sherif A, European Association of U. EAU guidelines on muscle-invasive and metastatic bladder cancer: summary of the 2013 guidelines. Eur Urol. 2014;65(4):778–92.PubMedCrossRef
26.
go back to reference Ha YS, Jeong P, Kim JS, Kwon WA, Kim IY, Yun SJ, Kim GY, Choi YH, Moon SK, Kim WJ. Tumorigenic and prognostic significance of RASSF1A expression in low-grade (WHO grade 1 and grade 2) nonmuscle-invasive bladder cancer. Urology. 2012;79(6):1411 e1411–6.CrossRef Ha YS, Jeong P, Kim JS, Kwon WA, Kim IY, Yun SJ, Kim GY, Choi YH, Moon SK, Kim WJ. Tumorigenic and prognostic significance of RASSF1A expression in low-grade (WHO grade 1 and grade 2) nonmuscle-invasive bladder cancer. Urology. 2012;79(6):1411 e1411–6.CrossRef
27.
go back to reference Rawson NS, Peto J. An overview of prognostic factors in small cell lung cancer. A report from the Subcommittee for the Management of lung Cancer of the United Kingdom coordinating committee on Cancer research. Br J Cancer. 1990;61(4):597–604.PubMedPubMedCentralCrossRef Rawson NS, Peto J. An overview of prognostic factors in small cell lung cancer. A report from the Subcommittee for the Management of lung Cancer of the United Kingdom coordinating committee on Cancer research. Br J Cancer. 1990;61(4):597–604.PubMedPubMedCentralCrossRef
28.
go back to reference Tan X, Xiao K, Liu W, Chang S, Zhang T, Tang H. Prognostic factors of distal cholangiocarcinoma after curative surgery: a series of 84 cases. Hepatogastroenterology. 2013;60(128):1892–5.PubMed Tan X, Xiao K, Liu W, Chang S, Zhang T, Tang H. Prognostic factors of distal cholangiocarcinoma after curative surgery: a series of 84 cases. Hepatogastroenterology. 2013;60(128):1892–5.PubMed
30.
go back to reference Whyard T, Waltzer WC, Waltzer D, Romanov V. Metabolic alterations in bladder cancer: applications for cancer imaging. Exp Cell Res. 2016;341(1):77–83.PubMedCrossRef Whyard T, Waltzer WC, Waltzer D, Romanov V. Metabolic alterations in bladder cancer: applications for cancer imaging. Exp Cell Res. 2016;341(1):77–83.PubMedCrossRef
Metadata
Title
Association between De Ritis ratio (aspartate aminotransferase/alanine aminotransferase) and oncological outcomes in bladder cancer patients after radical cystectomy
Authors
Yun-Sok Ha
Sang Won Kim
So Young Chun
Jae-Wook Chung
Seock Hwan Choi
Jun Nyung Lee
Bum Soo Kim
Hyun Tae Kim
Eun Sang Yoo
Tae Gyun Kwon
Won Tae Kim
Wun-Jae Kim
Tae-Hwan Kim
Publication date
01-12-2019
Publisher
BioMed Central
Published in
BMC Urology / Issue 1/2019
Electronic ISSN: 1471-2490
DOI
https://doi.org/10.1186/s12894-019-0439-7

Other articles of this Issue 1/2019

BMC Urology 1/2019 Go to the issue